| 10 0 (0%) | 04-03 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 11.68 |
1-year : | 13.64 |
| Resists | First : | 10 |
Second : | 11.68 |
| Pivot price | 9.91 |
|||
| Supports | First : | 9.9 |
Second : | 9.85 |
| MAs | MA(5) : | 9.93 |
MA(20) : | 9.91 |
| MA(100) : | 9.41 |
MA(250) : | 6.9 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 83.8 |
D(3) : | 77.3 |
| RSI | RSI(14): 65.9 |
|||
| 52-week | High : | 10.3 | Low : | 3.49 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ APEN ] has closed Bollinger Bands are 90.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 71 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 10.01 - 10.05 | 10.05 - 10.09 |
| Low: | 9.82 - 9.86 | 9.86 - 9.91 |
| Close: | 9.93 - 10 | 10 - 10.07 |
Apollo Endosurgery, Inc., a medical technology company, focuses on the design, development, and commercialization of medical devices. The company offers OverStitch and OverStitch Sx Endoscopic Suturing Systems that enable advanced endoscopic procedures by allowing physicians to sutures and secure the approximation of tissue through a flexible endoscope. It also provides Orbera, an intragastric balloon system that reduces stomach capacity causing patients to consume less following the procedure, as well as delays gastric content emptying under the Orbera Intragastric Balloon System, BIB, and Orbera365 Managed Weight Loss System brands. Additionally, the company offers X-Tack Endoscopic HeliX Tacking System, a suture-based device for closing and healing defects in the lower and upper gastrointestinal tract. The company sells its products to medical services providers; and hospitals, outpatient surgical centers, clinics, and physicians in the United States, Australia, Costa Rica, and other European countries. Apollo Endosurgery, Inc. was founded in 2005 and is headquartered in Austin, Texas.
Tue, 16 Apr 2024
Down 21.9% in 4 Weeks, Here's Why You Should You Buy the Dip in Apollo Endosurgery, Inc. (APEN) - Yahoo Lifestyle Australia
Tue, 04 Apr 2023
Boston Scientific completes Apollo Endosurgery acquisition - Mass Device
Tue, 29 Nov 2022
Boston Scientific to acquire Apollo Endosurgery for $615M - Mass Device
Tue, 29 Nov 2022
How Apollo Endosurgery's OverStitch helps patients lose weight - Medical Design & Outsourcing
Tue, 29 Nov 2022
Apollo Endosurgery to be Acquired by Boston Scientific - Yahoo Finance
Tue, 29 Nov 2022
Boston Scientific enters bariatric market with $417M acquisition of Apollo Endosurgery - BioWorld Online
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 48 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 5.2 (%) |
| Held by Institutions | 77.2 (%) |
| Shares Short | 462 (K) |
| Shares Short P.Month | 566 (K) |
| EPS | -1.05 |
| EPS Est Next Qtrly | -0.38 |
| EPS Est This Year | -2.07 |
| EPS Est Next Year | -1.3 |
| Book Value (p.s.) | 1.01 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0.89 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | -9.53 |
| PEG Ratio | 0 |
| Price to Book value | 9.8 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | 2016-12-29 |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|